Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TSG-01 for chronic heart failure due to coronary heart disease (Qi deficiency and blood stasis pattern)
CTR20191507Phase 2Completed
- Sponsor
- Shanghai Hongyitang Biopharmaceutical Technology
- Start
- Aug 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TSG-01 in chronic heart failure (CHF), coronary arteriosclerosis, sponsored by Shanghai Hongyitang Biopharmaceutical Technology. Started Aug 2019; status: completed.
02
Drugs
TSG-01
03
Conditions
chronic heart failure (CHF)coronary arteriosclerosis
Beyond the preview
Go deeper on CTR20191507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191507.